Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

trial for ANA773 in cancer patients in February and this study of ANA598 underway, Anadys is now focused on achieving important clinical milestones in both programs."

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical studies, including 28-day GLP toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern affecting approximately 2.7 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. The majority of infected individuals are unaware of their infection status and the large majority of individuals who know their status do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Since last month,s FBI shutdown ... known as the leading online black market for illegal ... in its offering of drugs and other illegal items.  ... takedowns did succeed in lowering the numbers of drugs ... the markets in August. But some new sites that ...
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... and Volcano Corporation (NASDAQ: VOLC ), a global ... today announced that they have entered into a definitive merger ... offer to acquire all of the issued and outstanding shares ... equity purchase price of USD 1 billion (approx. EUR 800 ...
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... March 11, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced that it will present ... be held from March 21st to 25th at the Conrad ... Mr. Ronald Ede, Chief Financial Officer; Ms. May Li, Director ...
... 2011 Sanofi-aventis (EURONEXT: SAN and NYSE: ... REGN ) today announced results from the ... (VEGF Trap) for the second-line treatment of non-small cell ... to the chemotherapy drug docetaxel did not meet the ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, ... addictive than traditional cigarettes, new research finds. Even ... cigarettes, thousands of ex-smokers said they have fewer cravings and ... need to smoke, researchers reported. "The pattern ... e-cig use than for tobacco use," said lead researcher Jonathan ...
(Date:12/21/2014)... Parker & Sons, Inc. a market leader ... other similar home contractor services announces a record number ... expert contracting services. The company is considered by many ... Arizona for well over 40 years. Parker and Sons ... quality customer service to the residents and business owners ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at ... of its kind, the site has provided its faithful users ... years running. It uniquely combines the benefits of platforms ... available to the masses. Assuring the potent herb’s followers ... of public approval. , Shane Chattin, Owner of ...
(Date:12/20/2014)... 21, 2014 MissyDress, a distinguished special ... prom lovers. The business has drastically cut prices to ... to everyone until Jan. 30, 2015. Many of the ... dresses, V-neck dresses, lace dresses, and more. , A ... there every day. Whether A-line princess prom dresses or ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... Urges Enrollment, LOS ANGELES, Oct. 3 For ... trials are being conducted to seek a,treatment, perhaps even ... disease that affects more than 1.5 million Americans -- ... that clinical trials answer is, "Will this drug help,people ...
... service, ... sacrifice and innovation, LOS ANGELES, ... healthcare heroes, Cherokee Uniforms announced today,10 winners of the 2007 ... winners represent a cross-section of,healthcare facilities, from VA medical centers ...
... Foundation for,AIDS Research, today announced several key appointments to ... Kenneth Cole named Sharon Stone to the position,of Global ... Diana L. Taylor to the Foundation,s Board of Trustees. ... performer and,humanitarian Harry Belafonte and Edward L. Milstein, a ...
... Findings Underscore Need for Medicare Market Basket Update;,MedPAC ... Funding,Requirements, WASHINGTON, Oct. 3 The Alliance ... BDO Seidman study of the nation,s,Medicaid program released ... worsening problem: Medicare,s cross-subsidization of increasingly,inadequate Medicaid payments ...
... National Strategic Partnership will help others live their ... raising awareness of diabetes,and important life-planning issues, ... (ADA) today announced that the Dignity Memorial,network, North ... to fighting diabetes as the ADA,s new National ...
... the life science industry has grown by leaps and ... can be daunting. Career Opportunities in Biotechnology and ... Spring Harbor Laboratory Press ( www.cshlpress.com ), provides an ... on tailoring a job search, and guidance on making ...
Cached Medicine News:Health News:Clinical Trials for Lupus Underway After Decades of Drought 2Health News:National 'Cherokee Inspired Comfort Award' Winners Announced 2Health News:National 'Cherokee Inspired Comfort Award' Winners Announced 3Health News:National 'Cherokee Inspired Comfort Award' Winners Announced 4Health News:National 'Cherokee Inspired Comfort Award' Winners Announced 5Health News:amfAR Appoints New Leadership as AIDS Research Organization Extends Its Global Reach 2Health News:amfAR Appoints New Leadership as AIDS Research Organization Extends Its Global Reach 3Health News:amfAR Appoints New Leadership as AIDS Research Organization Extends Its Global Reach 4Health News:New Study Spotlights Growing Role of Medicare in Propping Up Nation's Medicaid Program 2Health News:American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network 2Health News:American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network 3Health News:The hottest jobs in science, and how to land them 2
Body Suit w/Bra above knee...
Gynecomastia Vest...
Male Compression Vest, Front Closure...
Female Mini-VEST, Front Closure, X-Firm...
Medicine Products: